title: The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine.
abstract: The selective serotonin reuptake inhibitor fluoxetine is administered as a racemic mixture, and R- and S-fluoxetine are metabolized in the liver by N-demethylation to R- and S-norfluoxetine, respectively. R- and S-fluoxetine and S-norfluoxetine are equally potent selective serotonin reuptake inhibitors, but R-norfluoxetine is 20-fold less potent in this regard. Racemic fluoxetine and norfluoxetine are potent inhibitors of cytochrome P450 (CYP) 2D6 in vivo and in vitro and recent studies in vivo have shown that racemic fluoxetine is metabolized by CYP2D6. The primary aim of the present study was to investigate the stereoselective metabolism of fluoxetine and norfluoxetine by CYP2D6 in vivo. A single oral dose of fluoxetine (60 mg) was administered to six poor and six extensive metabolizers of sparteine. Blood samples were collected during 6 weeks for poor metabolizers and 3 weeks for extensive metabolizers. Once a week a sparteine test was performed. The R- and S-enantiomers of fluoxetine and norfluoxetine were determined by a stereoselective gas chromatography-mass spectroscopy method. In the poor metabolizers, the oral clearance of R- and S-fluoxetine was 3.0 l/h and 17 l/h, respectively, the corresponding values in the extensive metabolizers were 36 l/h and 40 l/h, respectively. For both enantiomers, the phenotype difference was statistically significant. In poor metabolizers, the elimination half-lives were 6.9 days and 17.4 days for R- and S-norfluoxetine, respectively, and in the extensive metabolizers it was 5.5 days for both enantiomers, a significant phenotypical difference only for S-norfluoxetine. For fluoxetine the elimination half-lives were 9.5 and 6.1 days in poor metabolizers for the R- and S-enantiomer, respectively. The corresponding values in the extensive metabolizers were 2.6 and 1.1 days, respectively. Also for this parameter, the differences were statistically significant. This study shows that CYP2D6 catalyses the metabolism of R- and S-fluoxetine and most likely the further metabolism of S-norfluoxetine but not of R-norfluoxetine.
authors: Department of Clinical Pharmacology, Institute of Medical Biology, Odense University, Denmark. l.fjordside@winsloew.ou.dk
authors: L
authors: L
authors: Fjordside
authors: U
authors: U
authors: Jeppesen
authors: C B
authors: CB
authors: Eap
authors: K
authors: K
authors: Powell
authors: P
authors: P
authors: Baumann
authors: K
authors: K
authors: Brøsen
mesh_terms: D019540:Area Under Curve; D005473:Fluoxetine / Q000378:metabolism* / Q000493:pharmacokinetics; D006207:Half-Life; D006801:Humans; D012016:Reference Values; D017367:Selective Serotonin Reuptake Inhibitors / Q000378:metabolism* / Q000493:pharmacokinetics; D013034:Sparteine / Q000378:metabolism*; D013237:Stereoisomerism
chemical_list: D005473:Fluoxetine; D017367:Selective Serotonin Reuptake Inhibitors; D013034:Sparteine